MBX Biosciences, Inc. (MBX)

MBX Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	12.5	30.52	24.21
Short-Term Investments	42.76	50.15	18.25
Cash & Short-Term Investments	55.26	80.68	42.46
Cash Growth	-	90.00%	-
Other Receivables	0.16	0.21	0.14
Receivables	0.16	0.21	0.14
Prepaid Expenses	3.13	2.45	1.52
Other Current Assets	0.24	0.13	0.08
Total Current Assets	58.8	83.47	44.21
Property, Plant & Equipment	1.28	0.67	0.84
Other Long-Term Assets	0.05	0.05	0.04
Total Assets	62.88	84.18	45.1
Accounts Payable	3.22	1.39	0.98
Accrued Expenses	4.82	2.38	2.32
Current Portion of Leases	0.16	0.15	0.14
Total Current Liabilities	8.2	3.93	3.43
Long-Term Leases	0.09	0.17	0.32
Other Long-Term Liabilities	0.13	0.19	0.07
Total Liabilities	8.41	4.29	3.82
Common Stock	0	0	0
Additional Paid-In Capital	5.91	3.05	0.41
Retained Earnings	-103.78	-75.58	-43.02
Comprensive Income & Other	-0.02	0.06	0
Total Common Equity	-97.89	-72.47	-42.61
Shareholders' Equity	54.47	79.89	41.27
Total Liabilities & Equity	62.88	84.18	45.1
Total Debt	0.25	0.32	0.46
Net Cash (Debt)	55.01	80.35	42
Net Cash Growth	-	91.31%	-
Net Cash Per Share	3.91	6.56	5.24
Filing Date Shares Outstanding	15.83	15.11	8.02
Total Common Shares Outstanding	15.83	15.11	8.02
Working Capital	50.6	79.54	40.78
Book Value Per Share	-6.18	-4.80	-5.31
Tangible Book Value	-97.89	-72.47	-42.61
Tangible Book Value Per Share	-6.18	-4.80	-5.31
Machinery	0.99	0.24	0.23
Construction In Progress	0.02	0	-
Leasehold Improvements	0.39	0.37	0.35

Source: S&P Capital IQ. Standard template. Financial Sources.